Please login to the form below

Not currently logged in
Email:
Password:

Hisun

This page shows the latest Hisun news and features for those working in and with pharma, biotech and healthcare.

Pfizer cuts 2013 forecast after weak first quarter

Pfizer cuts 2013 forecast after weak first quarter

of $490m from the transfer of certain product rights to its China-based joint venture with Hisun.

Latest news

  • Pharma's biggest news stories in 2011

    and Pfizer announced plans to work with both Zhejiang Hisun Pharmaceuticals and Shanghai Pharmaceuticals Co.

  • Pfizer/Hisun to collaborate in China

    Pfizer has announced it is to work with Zhejiang Hisun Pharmaceuticals to develop and market generic drugs in China. ... Hua Bai, CEO and president of Hisun Pharmaceuticals, stated that such deals were the way forward for the company.

  • News in brief, July 04, 2007

    Hisun Pharma to form JV with Spanish company. Zhejiang Hisun Pharmaceutical, which is one of China's biggest active pharmaceutical ingredient producers, has signed a letter of intent with an unnamed

More from news
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Pharma deals during January 2013 Pharma deals during January 2013

    Watson continues to extend its women's health franchise. Picking up on several of last year's deal trends, Zhejiang Hisun reported the closure of an exclusive option to access ... risk in anything un-partnered past the end of phase II. So the deployment

  • Biosimilars in China Biosimilars in China

    Several joint venture deals between MNCs and Chinese players have been sealed recently: Hisun with Pfizer, Simcere with Merck and Fosun with Lonza.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics